Assessing the efficacy of spironolactone on adult acne in subjects with polycystic ovary syndrome

Aim: The present prospective clinical study was conducted to assess the long‑term spironolactone therapy and its effect with without dietary‑induced weight‑loss, on insulin levels, lipid profile, features in females PCOS (polycystic ovary syndrome). Methods: included 22 12 normal weight 10 obese within age of 17-32 years having symptoms including hyperandrogenism or biochemical evidence amenorrhea and/or oligomenorrhea. These subjects were assessed before after 100mg/day orally for months. Lifestyle modification advised females. Before starting following antiandrogen therapy, metabolic, endocrine, parameters assessed. Results: Spironolactone resulted a significant reduction triglycerides overweight an increase HDL (high-density lipoproteins) who lean have weight. After months oral area under curve insulin, resistance hemostasis model, levels during OGTT at 60 minutes significantly reduced In no negative change sensitivity secretion loss seen pharmacologic treatment.